 Sialic Acid Binding Ig-like Lectin 2
"Sialic Acid Binding Ig-like Lectin 2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A lectin and cell adhesion molecule found in B-LYMPHOCYTES. It interacts with SIALIC ACIDS and mediates signaling from B-CELL ANTIGEN RECEPTORS.
| Descriptor ID |
D051918
|
| MeSH Number(s) |
D12.776.395.550.200.810 D12.776.503.921.200 D12.776.543.550.200.810 D23.050.301.350.720
|
| Concept/Terms |
Sialic Acid Binding Ig-like Lectin 2- Sialic Acid Binding Ig-like Lectin 2
- Sialic Acid Binding Ig like Lectin 2
- CD22 Glycoprotein
- Glycoprotein, CD22
- Siglec-2
- Antigens, CD22
- CD22 Antigens
- B-Lymphocyte Cell Adhesion Molecule
- B Lymphocyte Cell Adhesion Molecule
- CD22 Antigen
- Antigen, CD22
|
Below are MeSH descriptors whose meaning is more general than "Sialic Acid Binding Ig-like Lectin 2".
Below are MeSH descriptors whose meaning is more specific than "Sialic Acid Binding Ig-like Lectin 2".
This graph shows the total number of publications written about "Sialic Acid Binding Ig-like Lectin 2" by people in this website by year, and whether "Sialic Acid Binding Ig-like Lectin 2" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2009 | 0 | 1 | 1 | | 2013 | 0 | 1 | 1 | | 2014 | 0 | 1 | 1 | | 2015 | 1 | 0 | 1 | | 2017 | 1 | 0 | 1 | | 2018 | 1 | 0 | 1 | | 2019 | 1 | 0 | 1 | | 2020 | 0 | 1 | 1 | | 2021 | 2 | 0 | 2 | | 2022 | 0 | 1 | 1 | | 2025 | 2 | 2 | 4 | | 2026 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Sialic Acid Binding Ig-like Lectin 2" by people in Profiles.
-
Silbert SK, Gava F, Yates B, Rankin AW, Rocco JM, Shao L, Dreyzin A, Cai Y, Lamplugh C, Han KL, Prochazkova M, Little L, Foley T, Sankaran H, Martin K, Garces P, Jin P, Chien CD, Taylor N, Fry TJ, Yuan CM, Wang HW, Stroncek DF, Highfill SL, Shalabi H, Shah NN. CD19/CD22 bivalent CAR T cells in children, adolescents and young adults with B-ALL: final phase 1 trial results. J Immunother Cancer. 2026 Jun 05; 14(6).
-
Dreyzin A, Yates B, Shalabi H, Silbert SK, Wang HW, Yuan CM, Hoang CN, Culbert AA, Gava F, Nair MS, Giordani VM, Little L, Foley T, Nussenblatt V, Fry TJ, Stroncek DF, Highfill SL, Shah NN. Ten-year experience of CD22 CAR T cells for children and young adults with B-cell acute lymphoblastic leukemia. Blood Adv. 2026 Mar 10; 10(5):1700-1712.
-
DeGolier KR, Pham-Danis C, Burciaga SD, Walsh ZH, Brzezinski C, Novak AJ, Leach L, Cimons J, Li W, Zhongyu Z, Dimitrov D, Scott-Browne JP, Kohler ME, Fry TJ. Rational redesign of antigen binding domain improves in vivo efficacy of the CD22-CAR. Mol Ther. 2026 Apr 01; 34(4):2175-2188.
-
Rankin AW, Pham-Danis C, Novak AJ, Danis E, Fry TJ, Kohler ME. Increased NFAT activity with dual CAR stimulation in CD19xCD22 CAR T-cells is associated with decreased exhaustion and improved survival. J Immunother Cancer. 2025 Nov 13; 13(11).
-
Dreyzin A, Kramer AM, Yates B, Wang HW, Sahaf B, Yuan C, Klysz D, Tunuguntla R, Ehlinger Z, Reitberg S, Adebola S, Su A, Ebina-Shibuya R, Jia D, Achar S, Patil S, Martin K, Jeyakumar N, Davis KL, Fry T, Mackall CL, Taylor N, Altan-Bonnet G, Highfill S, Feldman S, Stroncek DF, Chien C, Schultz LM, Frank MJ, Muffly LS, Shalabi H, Ramakrishna S, Shah NN. Outcomes following CD22 CAR T-cells in B-ALL: a tale of two manufacturing strategies. Cytotherapy. 2026 Mar; 28(3):101990.
-
Pham-Danis C, Novak AJ, Danis E, McClellan SM, Leach L, Yarnell MC, Ebmeier CC, Tasian SK, Kohler ME. Restoration of LAT activity improves CAR TÂ cell sensitivity and persistence in response to antigen-low acute lymphoblastic leukemia. Cancer Cell. 2025 Mar 10; 43(3):482-502.e9.
-
Shah NN, Fry TJ. The CD19neg needle in the haystack. Blood. 2022 07 07; 140(1):4-6.
-
Lichtenstein DA, Schischlik F, Shao L, Steinberg SM, Yates B, Wang HW, Wang Y, Inglefield J, Dulau-Florea A, Ceppi F, Hermida LC, Stringaris K, Dunham K, Homan P, Jailwala P, Mirazee J, Robinson W, Chisholm KM, Yuan C, Stetler-Stevenson M, Ombrello AK, Jin J, Fry TJ, Taylor N, Highfill SL, Jin P, Gardner RA, Shalabi H, Ruppin E, Stroncek DF, Shah NN. Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells. Blood. 2021 12 16; 138(24):2469-2484.
-
Spiegel JY, Patel S, Muffly L, Hossain NM, Oak J, Baird JH, Frank MJ, Shiraz P, Sahaf B, Craig J, Iglesias M, Younes S, Natkunam Y, Ozawa MG, Yang E, Tamaresis J, Chinnasamy H, Ehlinger Z, Reynolds W, Lynn R, Rotiroti MC, Gkitsas N, Arai S, Johnston L, Lowsky R, Majzner RG, Meyer E, Negrin RS, Rezvani AR, Sidana S, Shizuru J, Weng WK, Mullins C, Jacob A, Kirsch I, Bazzano M, Zhou J, Mackay S, Bornheimer SJ, Schultz L, Ramakrishna S, Davis KL, Kong KA, Shah NN, Qin H, Fry T, Feldman S, Mackall CL, Miklos DB. CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nat Med. 2021 08; 27(8):1419-1431.
-
Shah NN, Highfill SL, Shalabi H, Yates B, Jin J, Wolters PL, Ombrello A, Steinberg SM, Martin S, Delbrook C, Hoffman L, Little L, Ponduri A, Qin H, Qureshi H, Dulau-Florea A, Salem D, Wang HW, Yuan C, Stetler-Stevenson M, Panch S, Tran M, Mackall CL, Stroncek DF, Fry TJ. CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial. J Clin Oncol. 2020 06 10; 38(17):1938-1950.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|